C4 Therapeutics, Inc. CCCC 深 沪
等待开盘 03-26 09:30:00 美东时间
2.6711
+0.171
+6.84%
华盛通- 最 高2.77
- 今 开2.57
- 成交量 102.58万股
- 最 低 2.57
- 昨 收 2.50
- 总市值 2.61亿
- 52周最高 3.82
- 市盈率 静 --
- 换手率 1.05%
- 52周最低 1.085
- 委 比 6.67%
- 总股本 9757.82万
- 历史最高 51.21
- 量 比 0.53
- 振 幅 8.00%
- 历史最低 1.06
- 每 手 1
- 风险率 0.51%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多C4 Therapeutics Starts Trial For New Multiple Myeloma Drug Combo
C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the first patient has been dosed with cemsidomide,
03-25 19:09
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma
Cemsidomide, an oral IKZF1/3 degrader, has initiated a Phase 1b trial in combination with elranatamab and dexamethasone for relapsed/refractory multiple myeloma (RRMM). This trial aims to evaluate safety, tolerability, and anti-myeloma activity in up to 54 patients, exploring doses of 50, 75, and 100 µg. Secondary endpoints include overall response rate and complete response rate. The trial is part of a broader strategy to support cemsidomide's u...
03-25 11:00
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
C4 Therapeutics granted 85,480 share stock options to a new employee, vesting over four years, with 25% after the first year and the rest in monthly installments. The exercise price matched the closing stock price on March 9, 2026.
03-09 20:01
美股大行评级 | 下调居多！多邻国、Elastic、Flutter、欧特克、Zscaler等遭多家机构下调目标价
今日重点评级关注：巴克莱：维持C4 Therapeutics"超配"评级，目标价从5美元升至7美元；富国银行：维持Agilon Health"超配"评级，目标价从1美元升至1.5美元
03-02 14:08
Earnings Summary: C4 Therapeutics Q4
The Q4 earnings report for C4 Therapeutics (NASDAQ:CCCC) was released on Thursd...
02-26 20:24
C4 Therapeutics Q4 EPS $(0.18) Beats $(0.31) Estimate, Sales $11.016M Beat $6.460M Estimate
C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.31) by 41.37 percent. This is a 63.27 percent increase over losses of $(0.49) per share from
02-26 20:22
美股大行评级 | 大摩将康宁目标价从103美元升至127美元；潜在涨幅1779.7%！IGC Pharma获Ascendiant Capital升目标价至5美元
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从4.75美元升至5美元；Brookline Capital：维持C4 Therapeutics"买入"评级，目标价从20美元升至30美元
02-24 10:27
C4 Therapeutics Doses First Patient In Phase 2 MOMENTUM Trial Of Oral Cemsidomide With Dexamethasone For Relapsed Refractory Multiple Myeloma
Enrollment for Phase 2 MOMENTUM Trial Expected to Be Completed in Q1 2027 Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026
02-23 20:07
C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma
C4 Therapeutics announced the initiation of the Phase 2 MOMENTUM trial for cemsidomide in combination with dexamethasone for relapsed/refractory multiple myeloma (RRMM). The trial aims to evaluate anti-myeloma activity and safety in approximately 100 patients. Cemsidomide, an oral IKZF1/3 degrader, is dosed over a 14-day on/14-day off schedule. The Phase 1b trial combining cemsidomide with elranatamab is expected to begin in Q2 2026. Enrollment f...
02-23 12:00
C4 Therapeutics Grants Stock Options to New Employee as Inducement
C4 Therapeutics Grants Stock Options to New Employee as Inducement C4 Therapeutics Inc. has announced the grant of non-qualified stock options to purchase 162,880 shares of common stock to a new employee. The stock options have an exercise price equal to the closing price of the company's stock on t
02-10 05:01
